[Continued anticoagulation for unprovoked venous thromboembolism: guidance through the maze of recent studies].
Recent American, European and Dutch guidelines recommend indefinite anticoagulation after a diagnosis of unprovoked venous thromboembolism in the absence of a high bleeding risk. The recommended approach would be to only stop anticoagulant therapy after three months in patients with one or more untreatable risk factors for bleeding such as prior major bleeding, uncorrectable hypertension or deep thrombocytopenia. Vitamin K-antagonists and direct oral anticoagulants (DOACs) were found to protect against recurrent venous thromboembolism at cost of major bleedings, although at a lower frequency than the number of prevented thrombotic events. Due to the lower risk of major bleeding than associated with vitamin K-antagonists, DOACs are the preferred treatment option for the long term treatment of unprovoked venous thromboembolism. Apixaban is available in a reduced dose for long-term treatment, and rivaroxaban in a reduced dose was recently shown to be more effective than aspirin.